2025
Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study
Tefera J, Kuhn T, Matuschewski N, Meister E, Nguyenová J, Kao T, Mutonga M, Bitar R, Kahl V, Zhang X, Shewarega A, Chapiro J, Madoff D. Portal and Hepatic Vein Embolization vs Portal Venous Embolization Alone in Cirrhotic and Non-cirrhotic Swine: A Pilot Study. Journal Of Vascular And Interventional Radiology 2025 PMID: 40043833, DOI: 10.1016/j.jvir.2025.02.028.Peer-Reviewed Original ResearchPost-embolizationCirrhotic groupPortal venous embolizationHepatic vein embolizationPortal venous phaseNon-cirrhotic groupStudent's t-testFLR hypertrophyFLR increaseVein embolizationVenous phaseEffects of PVELiver volumeCT scanVenous embolizationEmbolizationCirrhotic liverFour-week intervalsWeeksT-testFLRLiverPilot studyYorkshire pigsPVEPredictors of Delayed Surgery After Distal Radius Fracture: A Large National Database Study.
Ratnasamy P, Allam O, Kammien A, Joo P, Luo X, Grauer J. Predictors of Delayed Surgery After Distal Radius Fracture: A Large National Database Study. Orthopedics 2025, 48: e75-e80. PMID: 39933104, DOI: 10.3928/01477447-20250204-01.Peer-Reviewed Original ResearchConceptsDistal radius fracturesDelayed surgeryRadius fracturesImmediate surgeryClinical factorsDistal radius fracture surgeryTime of surgeryCohort of patientsDemographics of patientsNon-clinical factorsFracture surgeryIndependent predictorsRetrospective studySurgical timeImpact patient outcomesMultivariate analysisSurgerySmoking statusComorbidity burdenPatientsWeek 0 to 2Patient outcomesWeek 3WeeksNon-clinicalEfficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered.
Ogbuagu O, Avihingsanon A, Segal-Maurer S, Wang H, Jogiraju V, Singh R, Rhee M, Dvory-Sobol H, Sklar P, Molina J. Efficacy, safety, and pharmacokinetics of lenacapavir oral bridging when subcutaneous lenacapavir cannot be administered. AIDS 2025 PMID: 39912752, DOI: 10.1097/qad.0000000000004142.Peer-Reviewed Original ResearchTreatment-emergent AEClinical trialsVirologic suppressionRates of virologic suppressionPlasma concentrationsAdequate plasma concentrationsHIV-1 treatmentConfidence intervalsLens doseLens treatmentMedian durationLenacapavirSC doseHIV-1PharmacokineticsPosthoc analysisDoseWeeksEfficacyTrialsAnalysis of participantsTreatmentInjectionAntiretroviralsSafetyA multi-center study of symptoms in patients with esophageal cancer postoperatively: A networking analysis
Chen F, Shen Z, Xiong Y, Jiang Y, Zhou D, Guo J, Huang H, Knobf M, Ye Z. A multi-center study of symptoms in patients with esophageal cancer postoperatively: A networking analysis. European Journal Of Oncology Nursing 2025, 74: 102784. PMID: 39813978, DOI: 10.1016/j.ejon.2025.102784.Peer-Reviewed Original ResearchConceptsEsophageal cancerSymptom clustersDry mouthEating difficultiesCross-sectional surveyStudy of symptomsExploratory factor analysisSymptom burdenMulti-center studyBridge symptomsWeeks post-surgeryAcid indigestionPost-surgerySentinel symptomPatientsCancerMultiple centersSymptomsFactor analysisHeartburnCore symptomsBileWeeksCluster levelMouthIntegrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial
Edelman E, Dziura J, Deng Y, DePhilippis D, Ferguson T, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Integrated Stepped Alcohol Treatment With Contingency Management for Unhealthy Alcohol Use Among People With HIV: A Randomized Controlled Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2025, 98: 72-81. PMID: 39321757, DOI: 10.1097/qai.0000000000003534.Peer-Reviewed Original ResearchUnhealthy alcohol useSelf-reported abstinenceAlcohol useLost to follow-upContingency managementAlcohol use disorderRandomized controlled trialsSubstance use treatmentAlcohol abstinenceFollow-upUse disorderControlled trialsPWHAlcohol treatmentAbstinenceUse treatmentEvidence of abstinenceHIVWeeksMean proportionTreatmentTrialsAlcoholDaysParticipants
2024
Continuous Glucose Monitoring among Infants Born Very Preterm: Evidence for Accuracy in Neonatal Intensive Care
Bonet J, Guiducci S, Res G, Brigadoi S, Sen S, Montaldo P, Priante E, Santoro N, Trevisanuto D, Baraldi E, Dalla Man C, Galderisi A. Continuous Glucose Monitoring among Infants Born Very Preterm: Evidence for Accuracy in Neonatal Intensive Care. The Journal Of Pediatrics 2024, 278: 114416. PMID: 39579867, DOI: 10.1016/j.jpeds.2024.114416.Peer-Reviewed Original ResearchBlood glucoseContinuous glucose monitoringSensor glucoseNeonatal intensive care unitInfants born pretermWeeks of gestationNeonatal intensive careIntensive care unitVery pretermGlucose monitoringCare unitIntensive carePoint-of-care blood glucoseInfantsPretermNeonatesPaired measurementsCGM accuracyHoursBirthweightGestationGlucoseBirthWeeksLong-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies
Issa N, Chovatiya R, Talia J, Torres T, Eyerich K, Calimlim B, Yang Y, Pechonkina A, Moreira A, Grada A, Bunick C. Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. SKIN The Journal Of Cutaneous Medicine 2024, 8: s449. DOI: 10.25251/skin.8.supp.449.Peer-Reviewed Original ResearchAtopic dermatitisModerate-to-severe atopic dermatitisLong-term disease controlClinically meaningful responseProlonged systemic therapyProportion of patientsUpadacitinib treatmentOptimal treatment targetsSystemic therapyOptimal treatmentMeaningful responseJAK inhibitorsInterim analysisPatientsUpadacitinibLong-term maintenanceTreatment targetItchingOptimal outcomesWeeksDermatitisDisease controlOutcomesSkinPhase 3TEZEPELUMAB EFFECTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BIOMARKER LEVEL
Lugogo N, Chupp G, Corren J, Israel E, Molfino N, Martin N, Spahn J, Ambrose C. TEZEPELUMAB EFFECTS ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BIOMARKER LEVEL. Annals Of Allergy Asthma & Immunology 2024, 133: s53-s54. DOI: 10.1016/j.anai.2024.08.184.Peer-Reviewed Original ResearchInflammatory biomarker levelsBaseline biomarker levelsBiomarker levelsPost hoc pooled analysisEffect of tezepelumabBaseline to weekLevels of FeNOSerum total IgESerum total IgE.Absolute percentage changeIncreased levelsDouble-blindPlacebo-controlledTezepelumabTotal IgEInflammatory biomarkersParallel-groupUncontrolled asthmaFeNOPatientsPercentage changeBiomarkersPlaceboWeeksBaselineACHIEVEMENT OF ITCH-FREE STATE AND SLEEP IMPROVEMENT WITH TAPINAROF IN TWO PIVOTAL ATOPIC DERMATITIS TRIALS
Simpson E, Siri D, Chovatiya R, Shahriari M, Burnette A, Craiglow B, Brown P, Tallman A. ACHIEVEMENT OF ITCH-FREE STATE AND SLEEP IMPROVEMENT WITH TAPINAROF IN TWO PIVOTAL ATOPIC DERMATITIS TRIALS. Annals Of Allergy Asthma & Immunology 2024, 133: s9. DOI: 10.1016/j.anai.2024.08.055.Peer-Reviewed Original ResearchPatient Oriented Eczema MeasurePP-NRSAtopic dermatitisWeek 8Sleep disturbancePeak Pruritus Numerical Rating ScalePruritus Numerical Rating ScaleNumerical rating scaleAnalyzed post hocStatistically significant improvementEvaluate sleep disturbancesRating ScaleSleep improvementTapinarofWeek 1Itch reductionScore improvementTreatment groupsBaseline scoresItchingWeeksPost-hocSleepPatientsOutcomesImproving Time to Goals of Care Discussions in Invasively Ventilated Preterm Infants.
Gentle S, Cohen C, Carlo W, Winter L, Hallman M. Improving Time to Goals of Care Discussions in Invasively Ventilated Preterm Infants. Pediatrics 2024, 154 PMID: 39359206, PMCID: PMC11524032, DOI: 10.1542/peds.2024-066585.Peer-Reviewed Original ResearchConceptsPostmenstrual ageBronchopulmonary dysplasiaPreterm infantsTracheostomy placementWeeks' PMA.Identifying preterm infantsWeeks postmenstrual ageBPD infantsTracheostomy dependenceInvasive ventilationGoC discussionsVentilatory requirementsTracheostomyVentilator liberationInfantsHospital dischargeMultidisciplinary conferenceQuality improvement initiativesWeeksChart analysisUniversity of AlabamaSMART aimStatistical process control chartsProcess control chartsControl chart analysisMolecular mechanisms of Coxiella burnetii formalin-fixed cellular vaccine reactogenicity
Fratzke A, Szule J, Butler S, Schaik E, Samuel J. Molecular mechanisms of Coxiella burnetii formalin-fixed cellular vaccine reactogenicity. Infection And Immunity 2024, 92: e00335-24. PMID: 39356158, PMCID: PMC11556133, DOI: 10.1128/iai.00335-24.Peer-Reviewed Original ResearchCD4+ T cellsSmall cell variantWhole cell vaccineWeeks post-injectionSite of vaccinationT cellsCell variantPost-injectionAdoptive transfer experimentsLocal reactionsDelayed-type hypersensitivitySite of injectionCD8+Antigen persistenceCell vaccineQ-VaxCD4Mouse modelRod-shaped bacteriaHistological changesReactogenicityGuinea pigsVaccineCytokinesWeeksReturn-to-Play After Plasmodium falciparum Malaria in a Professional American Football Player
Mun J, Ryan E, Whalen J, Martin S. Return-to-Play After Plasmodium falciparum Malaria in a Professional American Football Player. JBJS Case Connector 2024, 14: e24.00457. PMCID: PMC11581430, DOI: 10.2106/jbjs.cc.24.00457.Peer-Reviewed Original ResearchPlasmodium falciparum malariaPersistent splenomegalyHigh-grade feverProfessional American football playersAmerican football playersFalciparum malariaFootball playersPatient's symptomsCollision sport athletesMalariaEmergency departmentReturn-to-playBlood smearsHospital admissionRisk of deconditioningSplenomegalyNoncontact activityPatientsSport athletesSymptomsWeeksPlasmodiumOn-fieldFeverSmears90-Day Complication and Readmission Rates for Geriatric Patients With Hip Fracture at Different Time Points From COVID-19 Positivity: A Database Study
Sanchez J, Jiang W, Dhodapkar M, Radford Z, Rubin L, Grauer J. 90-Day Complication and Readmission Rates for Geriatric Patients With Hip Fracture at Different Time Points From COVID-19 Positivity: A Database Study. JAAOS Global Research And Reviews 2024, 8: e24.00069. PMID: 39330875, PMCID: PMC11412709, DOI: 10.5435/jaaosglobal-d-24-00069.Peer-Reviewed Original ResearchConceptsHip fracture surgeryHip fractureGeriatric patientsFracture surgeryAdverse eventsRate of minor adverse eventsCOVID-19 diagnosisWeeks of surgeryMinor adverse eventsTime pointsAssociated with increased oddsComplication rateAssess complicationsCOVID-19 positivityCOVID-19 infectionMultivariate analysisSurgeryComplicationsPatientsDatabase studyReadmission ratesCare algorithmWeeksDiagnosisCOVID-19A Curriculum on Advanced Topics in Hypertension for Internal Medicine Residents
Gallagher B, Windish D. A Curriculum on Advanced Topics in Hypertension for Internal Medicine Residents. Southern Medical Journal 2024, 117: 556-561. PMID: 39227050, DOI: 10.14423/smj.0000000000001732.Peer-Reviewed Original ResearchInternal medicine residentsMedicine residentsRepeated-measures analysis of varianceChronic kidney diseaseSmall group sessionsRepeated-measures analysisMean confidence scoreHypertensive urgencySecondary hypertensionKidney diseaseHypertensionUS adultsImmediate postMulti-institutional surveyResident confidenceHypertension expertsPostcurriculum surveysOutpatient settingPostcurriculumPrecurriculumHalf-dayTime pointsWeeksTraining scoresAnalysis of variancePostvasectomy Semen Analysis Compliance With Utilization of a Mail-In Semen Analysis Kit
Gu C, Belarmino A, Kenfield S, Nolte D, Civello D, Smith J, Honig S, Mehta A, Punjani N, Lerner L. Postvasectomy Semen Analysis Compliance With Utilization of a Mail-In Semen Analysis Kit. Journal Of Urology 2024, 212: 899-906. PMID: 39093876, DOI: 10.1097/ju.0000000000004185.Peer-Reviewed Original ResearchConceptsPostvasectomy semen analysisUrological practiceLogistic regression modelsPatient compliancePoor patient complianceUnivariate logistic regression modelCompliance rateMultivariate logistic analysisPractice typeSemen analysisKIT activationNationwide cohortProspective dataLogistic analysisRegression modelsPeriod of observationPractice areaWeeksPostvasectomyUrologyPatientsReceive careImpact of relevant variablesKitZip codesSpesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial
Gottlieb A, Strober B, Kokolakis G, Merola J, Zheng M, Langley R, Tang M, Hofmann P, Thoma C, Warren R. Spesolimab Rapidly Improves Quality of Life in Patients with Generalized Pustular Psoriasis, as per Dermatology Life Quality Index Scores: Data from the Effisayil 2 Trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s409. DOI: 10.25251/skin.8.supp.409.Peer-Reviewed Original ResearchGeneralized pustular psoriasisDermatology Life Quality IndexDermatology Life Quality Index scoresGeneralized pustular psoriasis flaresPustular psoriasisVisits up to weekWeek 4Results Baseline characteristicsLength of diseaseLife Quality IndexLife-threatening diseasePlacebo groupHigh-doseSkin pustulesBaseline characteristicsSpesolimabFlare preventionPlaceboDLQI scoreQuality of lifePatientsWeeksPsoriasisScoresDiseaseDeucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
Korman N, Warren R, Bagel J, Armstrong A, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli L, Kisa R, Banerjee S, Blauvelt A. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. Journal Of Dermatological Treatment 2024, 35: 2371045. PMID: 38945549, DOI: 10.1080/09546634.2024.2371045.Peer-Reviewed Original ResearchConceptsMaintenance of responseModerate to severe plaque psoriasisOnset of actionSevere plaque psoriasisPlaque psoriasisApremilast-treated patientsEfficacy measuresOral placeboClinical responseCoprimary endpointsDeucravacitinibPsoriasis trialsWeek 8PlaceboPASIPatientsWeek 1WeeksEfficacyPsoriasisSPGABaselineSignificant improvementTrialsApremilastIntegrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, Khanna S, Berenson C, Wang E, Cohen S, Korman L, Lee C, Kelly C, Odio A, Cook P, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi D, Hasson B, McGovern B, von Moltke L, Pardi D. Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infectious Diseases And Therapy 2024, 13: 2105-2121. PMID: 38941068, PMCID: PMC11416444, DOI: 10.1007/s40121-024-01007-z.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsPhase 3 trialRCDI rateAnalysis of treatment-emergent adverse eventsTreatment-related treatment-emergent adverse eventsStandard-of-care antibioticsHigh-risk patientsClostridioides difficile infectionPreventing rCDIRenal impairment/failureAbdominal painRecurrent CDIEfficacy analysisAdverse eventsTreatment-relatedPrevent recurrencePrevalent comorbiditiesRCDIWeeksAntibioticsPatientsComorbiditiesEfficacyPlaceboMicrobiomeAchieved oxygen saturations and risk for bronchopulmonary dysplasia with pulmonary hypertension in preterm infants
Gentle S, Singh A, Travers C, Nakhmani A, Carlo W, Ambalavanan N. Achieved oxygen saturations and risk for bronchopulmonary dysplasia with pulmonary hypertension in preterm infants. Archives Of Disease In Childhood 2024, 109: 941-947. PMID: 38937062, PMCID: PMC11503043, DOI: 10.1136/archdischild-2024-327014.Peer-Reviewed Original ResearchConceptsBronchopulmonary dysplasia-associated pulmonary hypertensionOxygen saturation indexSurvival statusPreterm infantsPulmonary hypertensionHigher FiOLt;29 weeks' gestationFraction of inspired oxygenWeeks postmenstrual ageSingle-centre studyNon-invasive predictorCase-control studyPostmenstrual ageWeeks gestationBronchopulmonary dysplasiaRespiratory supportNon-survivorsInfantsOxygen saturationPatient outcomesPretermSurvivalHypertensionWeeksPredictorsEffect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial
Kahn S, Deanfield J, Jeppesen O, Emerson S, Boesgaard T, Colhoun H, Kushner R, Lingvay I, Burguera B, Gajos G, Horn D, Hramiak I, Jastreboff A, Kokkinos A, Maeng M, Matos A, Tinahones F, Lincoff A, Ryan D, Investigators S. Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial. Diabetes Care 2024, 47: 1350-1359. PMID: 38907683, PMCID: PMC11282386, DOI: 10.2337/dc24-0491.Peer-Reviewed Original ResearchCardiovascular diseaseMagnitude of weight reductionDouble-blind trialEffect of semaglutideCases of diabetesSubcutaneous semaglutideTreatment armsFollow-upSemaglutideDiabetesHbA1cObesityIntervention exposureGlycemiaPlaceboWeeksBody weightGlycemic outcomesDiseaseWeight reductionNormoglycemiaTrialsParticipantsProgressionKg/m2
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply